Vor Bio Q3 Loss Narrows to $86.7M; New $150M ATM Signed, Runway Into Early 2029

summarizeSummary

Vor Bio's Q3 2026 net loss fell to $86.7 million from $812.7 million a year ago, mostly on a smaller non-cash warrant remeasurement charge. With $481.6 million in cash and securities funding operations into early 2029, the company also put a new $150.0 million at-the-market program in place.

check_boxKey Events · Earnings and Guidance · VOR

• Q3 Loss Narrows Sharply

  Net loss was $86.7 million for the three months ended September 30, 2026 versus $812.7 million a year earlier, while the nine-month loss fell to $369.1 million from $2,418.8 million.

• Warrant Mark Drives the Gap

  The change in fair value of warrant liabilities was a $32.9 million charge this quarter versus $790.5 million in Q3 2025, a non-cash remeasurement tied to the share price and fewer outstanding warrants rather than new dilution or cash outflow.

• Runway Into Early 2029

  Cash, cash equivalents and marketable securities totaled $481.6 million at September 30, 2026, which management expects to fund operations into early 2029, past the UPSTREAM MG topline expected in the first half of 2027.

• New $150M ATM Replaces Stifel

  On October 30, 2026 the company signed an at-the-market sales agreement with William Blair and RBC for up to $150.0 million at up to 3.0% commission; the prior Stifel facility is fully used after $125.0 million of sales, including 2,558,569 shares at a $19.11 weighted average in Q3.

auto_awesomeAnalysis · VOR · Life Sciences

The headline is the swing in reported loss: $86.7 million this quarter versus $812.7 million a year ago. Almost all of that gap is non-cash. The change in fair value of liability-classified warrants was a $32.9 million charge this quarter against $790.5 million a year earlier, a mark-to-market move driven by the share price and a smaller warrant count, not a cash outflow and not new dilution. What matters for the thesis is the balance sheet: $481.6 million of cash and marketable securities funds operations into early 2029, covering the UPSTREAM MG topline expected in the first half of 2027 without an immediate raise. Against that, on October 30, 2026 the company signed a fresh $150.0 million at-the-market facility with William Blair and RBC at up to 3.0% commission, replacing the Stifel ATM now fully drawn at $125.0 million. That is an overhang, not a sale, since no shares have been sold under the new program. Operating expenses are climbing as the telitacicept Phase 3 programs scale: R&D rose to $34.5 million from $14.1 million and G&A to $23.9 million from $14.0 million year over year.